Zobrazeno 1 - 10 of 87 pro vyhledávání: '"Uma N M Rao"'
1
Akademický článek
Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab.
Autor: Ahmad A Tarhini, Howard Edington, Lisa H Butterfield, Yan Lin, Yongli Shuai, Hussein Tawbi, Cindy Sander, Yan Yin, Matthew Holtzman, Jonas Johnson, Uma N M Rao, John M Kirkwood
Publikováno v: PLoS ONE, Vol 9, Iss 2, p e87705 (2014)
We evaluated neoadjuvant ipilimumab in patients with surgically operable regionally advanced melanoma in order to define markers of activity in the blood and tumor as assessed at baseline (before ipilimumab) and early on-treatment. Patients were trea
Externí odkaz: https://doaj.org/article/39be333756984e23ba9e91a09d2aa842
Zobrazit plný text záznamu
3
Sixteen year-old with leiomyosarcoma in a prior benign myomectomy site
Autor: Kristen P. Zeligs, Kathleen M. Darcy, Thomas P. Conrads, Payam Katebi Kashi, Saeid Movahedi-Lankarani, Niccole B. Piguet, Ruchi Garg, Jennifer A. Vaz, Uma N. M. Rao, G. Larry Maxwell, Lana Bijelic
Publikováno v: Gynecologic Oncology Reports
Gynecologic Oncology Reports, Vol 29, Iss, Pp 126-129 (2019)
Uterine leiomyosarcoma in a prior myomectomy site is a rare phenomenon. We report an unusual case of a leiomyosarcoma arising six months post myomectomy in a 16-year old female.
Graphical Abstract Radiographic images (A) starting with the CT of
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1d41eb0afdc621b47c8aed69302bb81
http://europepmc.org/articles/PMC6726713
Zobrazit plný text záznamu
4
E3611—A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma
Autor: Mark A. Taylor, John M. Kirkwood, Jerry W Mitchell, Phu Van Truong, Ahmad A. Tarhini, Robert M. Conry, Mark R. Albertini, Xiaoxue Li, Noel Laudi, Arun Nagarajan, Uma N. M. Rao, Sandra J. Lee, Stuart J. Wong
Publikováno v: Clinical Cancer Research. 25:524-532
Purpose: Interferon-α favors a Th1 shift in immunity, and combining with ipilimumab (ipi) at 3 or 10 mg/kg may downregulate CTLA4-mediated suppressive effects, leading to more durable antitumor immune responses. A study of tremelimumab and high-dose
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::481900f87e00cc80d47ed818420784a4
https://doi.org/10.1158/1078-0432.ccr-18-2258
Zobrazit plný text záznamu
6
Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire
Autor: John M. Kirkwood, Yan Lin, Matthew P. Holtzman, Robert L. Ferris, James F. Pingpank, Prateek Mendiratta, Erik Yusko, Ahmad A. Tarhini, Zahra Rahman, Uma N. M. Rao, Priyanka Vallabhaneni, Huang Lin, Julie A. Rytlewski
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-10 (2018)
Journal for Immunotherapy of Cancer
Background Neoadjuvant immunotherapy utilizing novel combinations has the potential to transform the standard of care for locally/regionally advanced melanoma. We hypothesized that neoadjuvant ipilimumab in combination with high dose IFNα2b (HDI) is
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3f367068518c9ce09aa6e94cd69c329
http://link.springer.com/article/10.1186/s40425-018-0428-5
Zobrazit plný text záznamu
7
CDK8 Expression in Extrauterine Leiomyosarcoma Correlates With Tumor Stage and Progression
Autor: Oleksandr Yergiyev, Alka Palekar, Uma N. M. Rao, David L. Bartlett, George Garib, Karen E. Schoedel
Publikováno v: Applied Immunohistochemistry & Molecular Morphology. 26:161-164
Mediator is a multiprotein complex that acts as a versatile transcription coactivator in eukaryotes. CDK8 kinase complex is a 4-protein subunit of the mediator complex that can act as a transcriptional repressor or coactivator, depending on the speci
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b13a693721777403851831ae757f3221
https://doi.org/10.1097/pai.0000000000000409
Zobrazit plný text záznamu
9
Ossifying fibromyxoid tumor: a study of 6 cases of atypical and malignant variants
Autor: Oleksandr Yergiyev, Richard L. McGough, Uma N. M. Rao, Alka Palekar, Kossivi Dantey, Karen E. Schoedel
Publikováno v: Human Pathology. 60:174-179
Ossifying fibromyxoid tumors (OFMT) of soft parts are rare, slow-growing tumors that have potential for local recurrence and may metastasize. While OFMT originally was considered benign, several cases of malignant OFMT have been documented. There is
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99b842bcf3d2598139a0960581ba0152
https://doi.org/10.1016/j.humpath.2016.10.012
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje